PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...
News Medical on MSN13d
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeuticPheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...
News Medical on MSN13d
Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...
GlobalData on MSN13d
Pheno Therapeutics gains UK MHRA’s CTA for multiple sclerosis therapy trialDeveloped under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...
Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802. The small molecule therapeutic is designed to promote remyelination in ...
A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its small molecule therapeutic, PTD802. The ...
EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback